Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > How LTE suddenly became a cause of failure

<< Previous

Bullboard Posts

Next >>

Comment by mstrmndon Oct 21, 2021 7:34pm

373 Views

Post# 34035399

RE:RE:RE:RE:How LTE suddenly became a cause of failure

Misinformation spreading so let me out this right away.

ATB-429 parent moeity is Mesalamine. ATB-346 (Otenaproxesul) parent is Naproxen.

In last AME with 42 participants, 3/42 expected with LTE, when 5/42 observed with parent Naproxen.

All claims about long-term intolerability of ATB-429 for IBD are false. Lots of evidence to show Mesalamine is tolerated well long-term in IBD and adding H2S may improve mucosal healing properties without any significant adverse effects based on H2S insights from ATB-346.

GLTA